November 2026—NeoGenomics launched the PTEN IHC CDx, an immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The assay detects PTEN protein loss in prostate adenocarcinoma tissue using the Ventana PTEN (SP218) RxDx assay to identify patients who may be eligible for AstraZeneca’s FDA-approved targeted therapy Truqap (capivasertib).
PTEN IHC CDx is available as a standalone order or as part of Neo PanTracer Pro for prostate cancer, a molecular workup that combines comprehensive genomic profiling and cancer-type-directed IHC testing in a single order.
NeoGenomics, 239-768-0600